无菌性翻修髋膝关节置换使用非头孢唑林替代抗生素增加假体周围感染风险
单中心回顾性队列纳入2000年1月至2024年3月共5993例无菌性翻修关节置换(髋3429例、膝2564例),94%接受头孢唑林围手术期预防,4%发生假体周围感染。头孢唑林较非头孢唑林替代药物显著提高无PJI生存率(HR 0.5,P=0.006);术后口服头孢羟氨苄或头孢氨苄未显著降低感染风险;意外阳性培养发生率4%,与后续PJI无显著关联(HR 1.5,P=0.21)。
要点
- 无菌性翻修TJA中头孢唑林围手术期预防较替代药物显著降低PJI风险。
- 术后口服头孢羟氨苄或头孢氨苄未显著降低培养阴性患者的PJI风险。
- 意外阳性培养发生率4%,以凝固酶阴性葡萄球菌为主,与后续PJI无显著关联。
核心结论
- 围手术期头孢唑林预防是无菌性翻修TJA中可干预的关键保护因素,较非头孢唑林替代药物显著降低PJI风险。
- 术后延长口服抗生素对培养阴性患者无额外获益,意外阳性培养与后续PJI无显著关联。
研究设计与样本
- 单中心学术机构回顾性队列,纳入2000年1月至2024年3月无菌性翻修全髋和全膝关节置换共5993例(THA 3429例,TKA 2564例)。
- 按围手术期抗生素类型(头孢唑林 vs 非头孢唑林)、术后口服抗生素方案及术中培养结果分组,采用Cox比例风险回归分析无PJI生存率。
主要发现
- 94%的病例接受头孢唑林围手术期预防,共234例(4%)后续发生PJI。
- 头孢唑林围手术期预防较非头孢唑林替代药物显著提高无PJI生存率(HR 0.5,P=0.006)。
- 在接受头孢唑林的患者中,加用口服头孢羟氨苄或头孢氨苄较未用口服抗生素未显著降低PJI风险。
- 意外阳性培养发生率为4%,最常见为凝固酶阴性葡萄球菌(44%),与后续PJI无显著关联(HR 1.5,P=0.21)。
- 仅1例意外阳性培养病例后续发生PJI且微生物一致。
关键数值与推荐
- 围手术期头孢唑林预防较非头孢唑林替代药物:HR 0.5,P=0.006。
- 意外阳性培养与后续PJI关联:HR 1.5,P=0.21。
- 意外阳性培养发生率4%,其中凝固酶阴性葡萄球菌占44%。
临床怎么用
- 无菌性翻修TJA应优先标准化使用头孢唑林围手术期预防,而非非头孢唑林替代药物。
- 培养阴性患者术后不推荐常规延长口服抗生素预防PJI。
- 术中意外阳性培养需结合临床判断,不应仅据此常规延长抗生素疗程。
局限性
- 单中心回顾性设计,可能存在选择偏倚和未测量混杂。
- 原文未报告非头孢唑林替代药物的具体种类及使用原因。
- 原文未报告术后口服抗生素的具体疗程和剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although perioperative cefazolin antibiotic prophylaxis is associated with a reduced risk of periprosthetic joint infection (PJI) in primary total joint arthroplasty (TJA) compared to noncefazolin alternatives, its relative efficacy in the aseptic revision setting is less defined. Furthermore, the roles of postoperative oral antibiotic prophylaxis and the management of unexpected positive cultures (UPCs) remain controversial. Therefore, we examined PJI in aseptic revision TJA based on (1) perioperative antibiotic prophylaxis, (2) postoperative oral antibiotic regimen, and (3) UPC status. METHODS: We evaluated all patients undergoing aseptic revision total knee arthroplasty and total hip arthroplasty (THA) at a single academic institution between January 2000 and March 2024, yielding 5,993 revision arthroplasties (n = 3,429 THA, n = 2,564 total knee arthroplasty). Cases were analyzed based on perioperative antibiotic type (cefazolin versus noncefazolin), postoperative oral antibiotic regimen, and intraoperative culture results. Cox proportional hazards regressions were used to determine survivorship free from PJI. RESULTS: Among this cohort, 94% received cefazolin perioperative prophylaxis. In total, 234 cases (4%) subsequently developed PJI. Cefazolin perioperative prophylaxis was associated with significantly higher survivorship free from PJI compared to noncefazolin alternatives (hazard ratio: 0.5; P = 0.006). In patients receiving perioperative cefazolin, the addition of oral antibiotics with either cefadroxil or cephalexin did not significantly reduce PJI risk compared to no oral antibiotics. The incidence of UPCs was 4%, most commonly coagulase-negative Staphylococcus (44%), and was not significantly associated with subsequent PJI (hazard ratio: 1.5; P = 0.21). CONCLUSIONS: Perioperative cefazolin prophylaxis is a critical modifiable risk factor, providing a substantial protective effect against PJI in aseptic revision TJA. In contrast, extended oral antibiotic prophylaxis provided no additional benefit for culture-negative patients. While UPCs occurred in 4% of cases, only one case subsequently developed PJI with a concordant microorganism. These findings reinforce the importance of standardized cefazolin prophylaxis over alternative agents in aseptic revision TJA.
引用
- Panos JA, Mallinger BD, Virk A, et al. Increased Risk of Periprosthetic Joint Infection Following Aseptic Revision Hip and Knee Arthroplasty With the Use of Non-Cefazolin Alternative Antibiotics. J Arthroplasty. 2026. PMID: 42767527. doi:10.1016/j.arth.2026.09.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。